Antitumor effects of methylglyoxal-bis(N-4-methylthiosemicarbazone) and their potentiation in pyridoxine-deficient animals.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001377:Azaserine / Q000494:pharmacology; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004032:Diet; D004357:Drug Synergism; D005260:Female; D007942:Leukemia, Experimental / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy; D012510:Sarcoma 180 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013882:Thiosemicarbazones / Q000494:pharmacology*; D026681:Vitamin B 6 Deficiency